Avi Chinthala, M.S.

Avi joined BioTechLogic in 2025 as a Senior Consultant with a focus on Analytical Development and Quality workflows supporting R&D, pre-clinical, clinical and commercial development space. Avi’s expertise spans development, qualification, validation, tech transfer and establishment of analytical methods pertaining to biopharmaceutical analysis and CMC development – encompassing a diverse range of modalities like protein biologics, vaccines, viral vectors and nucleic acid therapies, with a special focus on CGT including CAR-T, mRNA and AAV.

Avi brings expertise in physico-chemical, cell-based bioassay, immune-based and molecular analytical technologies. He specializes in potency assay strategy and full spectrum potency workflow, encompassing phase-appropriate, GLP and GMP compliant documentation, data generation and in-lab execution. Avi also supports regulatory filings and quality aspects of the analytical workflow.

Before joining BioTechLogic, Avi worked at Imuege Ltd., a clinical stage immuno-oncology company developing CAR-T and viral vector therapies. Avi led the potency strategy for Imugene's lead CAR-T program in the clinic, and was supporting internal and outsourced analytical activities for plasmid, mRNA, AAV and CAR-T production, for AD and QC labs.

Before Imugene, Avi was at Precision BioSciences in the CMC-Analytical Development function, with increasing responsibilities, while supporting analytical workflows for CGT programs in late-stage research, process development, process validation, process tech transfer and clinical manufacturing. He served as the analytical lead and potency SME for Precision’s gene therapy and gene editing mRNA and AAV, and CAR-T cell therapy programs in the clinic. Avi developed novel potency assays, characterization & quantification methods, and led qualification, validation, tech transfer and execution activities in the AD and QC labs.

Avi brings CDMO experience from his time at Catalent Pharma Solutions supporting bioassay method development, validation and QC testing for biologics for late-stage clinical and commercial programs. Before that, Avi worked at GSK Vaccines where he worked as the analytical development SME on multiple CHO expressed vaccine candidates in development and clinic. Avi previously also worked at Novartis Vaccines supporting analytical development of various seasonal and pandemic influenza vaccine candidate production, performing full spectrum analytical testing from HPLC, LC-MS, residual HCP, HCDNA, CE, cell-based bio and immune-based quantitation assays. Avi also supported the self-amplifying mRNA technology for RNA-based influenza vaccine candidates with PCR, dPCR, sequencing, and other analytical techniques.

Northeastern University

M.S. in Biotechnology